Excited to partner with PharmaVOICE and be part of the upcoming WoW Virtual Event!
On March 3, we’re proudly sponsoring the one-day event, which brings together some of the life sciences industry’s most influential
News
Otto Damsma Joins Bioforum as Vice President of Asia Pacific Operations
We’re delighted to welcome Otto Damsma to Bioforum! Otto, who has more than 30 years of industry experience across biopharma,
PharmaVOICE 100 Celebration: A Conversation with RedHill Biopharma, Alkermes, and PharmaVOICE: “Developing Clinical Trial Outsourcing Strategies that Scale As Biotechs Do”
2020 has proven to be an incredibly pivotal time for the life sciences industry. While COVID-19 has created limitations around
On-Demand Webinar Recording: “5 Key Considerations When Selecting an EDC Provider”
On-Demand Webinar Recording: “5 Key Considerations When Selecting an EDC Provider” As EDC in clinical trials becomes an industry standard,
We’re pleased to announce that our very own Irina Sher, VP of Data Management, has been recognized by the Healthcare Technology Report as one of the Top 25 Women Leaders in Biotechnology in 2020!
The Healthcare Technology Report’s “2020 Top 25 Women Leaders in Biotechnology Award” We’re pleased to announce that our very own
PharmaVoice June Issue: A New Era of Clinical Trials
PharmaVoice June Issue: A New Era of Clinical Trials Bioforum’s Insights on how Industry Responds to the COVID-19 Pandemic Amir
Veeva and Bioforum Partner with RedHill Biopharma to Maximize Value of Opaganib Phase 2/3 COVID-19 Clinical Data
Veeva and Bioforum Partner with RedHill Biopharma to Maximize Value of Opaganib Phase 2/3 COVID-19 Clinical Data Veeva Vault CDMS
COVID-19 Support plan for Emerging Biopharma
COVID19 Support plan for Emerging Biopharma It’s is important to realise that every trial will (or already has been) impacted
Interim User Guide – COVID-19
Interim User Guide – COVID-19 CDISC have released an Interim User Guide, freely available on their website, for studies pertaining
Bioforum News – April 2020
Dear Colleagues and Friends, The ongoing spread of COVID-19 will continue to have major implications for clinical trial operations as
